蓝帆医疗涨2.09%，成交额6162.93万元，主力资金净流出92.47万元

Core Viewpoint - Bluefan Medical's stock has shown a positive trend recently, with a year-to-date increase of 4.64% and a 7.13% rise over the last five trading days, indicating potential investor interest and market confidence in the company [1]. Financial Performance - For the period from January to September 2025, Bluefan Medical reported a revenue of 4.182 billion yuan, reflecting a year-on-year decrease of 10.15%. The net profit attributable to shareholders was -286 million yuan, down 30.09% compared to the previous year [2]. - Cumulatively, since its A-share listing, Bluefan Medical has distributed a total of 1.348 billion yuan in dividends, with 403 million yuan distributed over the last three years [3]. Shareholder Information - As of December 19, 2025, the number of shareholders for Bluefan Medical reached 74,400, an increase of 1.86% from the previous period. The average number of circulating shares per shareholder decreased by 1.82% to 13,440 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 8.2141 million shares, a decrease of 8.6208 million shares from the previous period. The Medical Device ETF (159883) is a new entrant among the top ten shareholders, holding 4.9679 million shares [3]. Business Overview - Bluefan Medical, established on December 2, 2002, and listed on April 2, 2010, is located in Zibo, Shandong Province. The company specializes in cardiovascular health, health protection, and emergency care services. The revenue composition includes health protection products (70.08%), cardiovascular products (24.88%), emergency rescue products (3.72%), and others (1.32%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in medical devices and consumables, and is associated with various concepts such as long-term undervaluation and medical consumables [1].